Murphy & Mullick Capital Management Corp Purchases New Stake in Pfizer Inc. (NYSE:PFE)

Murphy & Mullick Capital Management Corp acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,875 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Pfizer in the fourth quarter valued at about $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Pfizer by 79.5% during the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock worth $295,760,000 after acquiring an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in shares of Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after acquiring an additional 4,726,549 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.56 on Wednesday. The company has a market cap of $144.96 billion, a P/E ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61. The business has a fifty day simple moving average of $26.14 and a 200-day simple moving average of $27.00. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.